9 analysts have expressed a variety of opinions on Pfizer PFE over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 8 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 3 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 3 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.22, a high estimate of $45.00, and a low estimate of $29.00. This upward trend is apparent, with the current average reflecting a 3.33% increase from the previous average price target of $40.86.
Breaking Down Analyst Ratings: A Detailed Examination
A comprehensive examination of how financial experts perceive Pfizer is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | $45.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | $45.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | $45.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | $45.00 |
| Terence Flynn | Morgan Stanley | Raises | Equal-Weight | $29.00 | $28.00 |
| Evan David Seigerman | BMO Capital | Raises | Outperform | $36.00 | $33.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | $45.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $45.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Pfizer. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Pfizer compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pfizer's stock. This examination reveals shifts in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pfizer's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Pfizer analyst ratings.
Delving into Pfizer's Background
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Breaking Down Pfizer's Financial Performance
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Pfizer's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -19.51%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pfizer's net margin excels beyond industry benchmarks, reaching 20.94%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Pfizer's ROE excels beyond industry benchmarks, reaching 3.44%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pfizer's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.39% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.74, Pfizer adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
